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OBJECTIVES The aim of our study was to evaluate the relationship between aldosterone synthase gene
polymorphism and cardiac dimensions in essential hypertension.
BACKGROUND Higher aldosterone synthase messenger ribonucleic acid levels in the human heart are
accompanied by increased intracardiac aldosterone production, a phenomenon that is
associated with cardiac fibrosis and hypertrophy. Recent evidence suggests that a polymor-
phism (344C/T) in the promoter region of the aldosterone synthase gene is associated with
increased constitutive aldosterone production.
METHODS Relationships between M-mode echocardiographic cardiac dimensions and aldosterone
synthase 344C/T polymorphism were studied in 210 never-treated, middle-aged patients
(age 41.6  1.4 years) affected by mild to moderate essential hypertension. Among these
patients, 48 had the genotype C344C, 97 had C344T, and 65 had T344T. Patients in
the three groups were similar in terms of age, gender, body mass index, and blood pressure.
RESULTS Left ventricular (LV) mass and thickness were positively correlated with the number of T
alleles: LV mass (CC, CT, and TT, respectively: 168  6.9, 179  5.2, and 193  6.9 g;
p  0.03), LV septal thickness (0.99  0.02, 1.03  0.02, and 11.08  0.03 cm, p  0.04),
PWT (0.93 0.03, 0.95 0.01, and 1.03 0.02 cm; p 0.002), and relative wall thickness
(38.3 1.2%, 38.8 0.8%, and 42.8 1.1%; p 0.004). This trend was confirmed by linear
regression, suggesting a “major gene” behavior for the T allele. Multiple regression analysis
showed that this effect was independent of anthropometric and clinical factors, including
adrenal aldosterone.
CONCLUSIONS Our data suggest that 344C/T polymorphism affects LV mass and thickness in essential
hypertension, independent of adrenal aldosterone. A role for intracardiac aldosterone
synthesis is hypothesized. (J Am Coll Cardiol 2004;43:265–70) © 2004 by the American
College of Cardiology Foundation
Left ventricular hypertrophy (LVH) is an important predic-
tor of cardiovascular morbidity and mortality in hyperten-
sive patients, as well as in the general population (1,2). It is
influenced by many variables, such as age, obesity, dietary
habits, pressure fluid overloads (3), and pharmacologic
treatment (4). Moreover, it has been previously demon-
strated that some vasoactive substances, such as angiotensin
II and aldosterone, acting as growth factors, may be asso-
ciated with the development of LVH (5). In the past few
years, particular attention has been focused on aldosterone,
for the following reasons: 1) myocardial and vascular fibrosis
were shown to be induced by this hormone (6–8); 2) the
Randomized ALdactone Evaluation Study (RALES) has
demonstrated that the combination of aldosterone antago-
nists and angiotensin-converting enzyme inhibitors can
reduce the mortality and morbidity from cardiac heart
failure; this effect does not appear to be due to the action of
spironolactone on sodium and potassium renal handling,
but implies a direct cardioprotective action of this drug (9);
3) intracardiac synthesis of aldosterone was found in isolated
rat hearts (10); 4) increased aldosterone synthase (CYP11B2)
expression was recently detected in biopsies from failing
human hearts, along with a direct relationship between
myocardial fibrosis and 11CYPB2 messenger ribonucleic
acid expression (11); and 5) increased aldosterone produc-
tion in the left ventricle (LV) of hypertensive patients,
compared with those with normotension, has recently been
demonstrated (12).
The 344C/T polymorphism falls in the promoter
region of the aldosterone synthase gene and is associated
with increased constitutive aldosterone production: in par-
ticular, the T allele is associated with increased plasma
aldosterone levels (13). Several studies of the association
between this polymorphism and left ventricular mass
(LVM) have been published (14–17), with controversial
results. This is not surprising, as LVM is not only modu-
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lated by environmental factors, but is also under polygenic
control. If not adequately minimized, environmental influ-
ences and genetic background may also modify or mask
genotype–phenotype relationships. As a consequence, only
highly homogeneous populations of patients sharing similar
environmental factors should be considered in analyses of
this association.
To provide further insight into the control of LV struc-
ture by CYP11B2 344C/T polymorphism in essential
hypertensive patients, we investigated a highly homoge-
neous population of only Caucasian middle-aged patients
with mild to moderate hypertension recently diagnosed and
never treated. To our knowledge, this is the first study to
follow these restrictive selection criteria. After this selection,
a positive association between the number of 344T alleles
and both LV thickness and mass was found.
METHODS
Patients. To minimize environmental confounding factors,
inclusion criteria were very restrictive. Patients were re-
quired: 1) to be of the same race (all Caucasian); 2) to have
only essential hypertension without collateral diseases with
cardiovascular implications; 3) to have not undergone phar-
macologic treatment for hypertension both before and
during the study; 4) to be not obese (body mass index of
30 kg/m2); and 5) to have normal sodium intake (24-h
sodium excretion of 300 mEq).
Thus, 210 (172 males and 38 females) never-treated
Caucasians (all Italians) with mild to moderate essential
hypertension were recruited into the study. All patients were
middle-aged and had a relatively short duration of hyper-
tension.
Blood pressure measurements. Hypertension was diag-
nosed by the contemporary presence of: 1) diastolic blood
pressure (BP) 85 mm Hg by daytime ambulatory BP
monitoring (Spacelabs 90207, Redmond, Washington); and
2) diastolic BP 90 mm Hg during office visits. Office BP
was measured with a mercury sphygmomanometer; for each
patient, all measurements were made by the same doctor
and during the same period of the day (8 to 10 AM). To
minimize the “white-coat” hypertensive effect, 10 office BP
measurements were recorded after the patient had been
clinically examined and after 10 min of rest in the supine
position. The last four measurements were averaged, and
this average was used for the diagnosis. The study protocol
was approved by the Ethics Committee of the San Raffaele
Hospital.
Biochemistry. Serum and urine electrolytes and creatinine
were measured by standard methods (ion-selective electrode
and autoanalyzer), and plasma renin activity (PRA) and
plasma aldosterone with a radioimmunoassay (DiaSorin,
Vercelli, Italy; and MedicalSystem SpA, Genova, Italy). To
have an estimate of the angiotensin II–independent rate of
aldosterone production, the aldosterone/PRA ratio was
computed for each patient.
Measurement of LVH. Patients underwent mono- and
bi-dimensional echocardiography using a Hewlett-Packard
imaging system (Sonos 2500 model, Palo Alto, California).
All measurements were performed by the same investigator
(Dr. Stella), who was blinded to the genotypes of the
patients.
Left ventricular internal diameters, septal thickness (ST),
and posterior wall thickness (PWT) were measured at end
diastole and end systole, according to the guidelines of the
American Society of Echocardiography (ASE) (18). Varia-
tion coefficients for septal and posterior wall end-diastolic
diameters, septal and posterior end-systolic diameters, and
LVM were 3%, 6%, 4%, 3%, and 5%, respectively. Techni-
cal error was calculated as the square root of the ratio
between the sum of squares of observations and the number
of observations/averages of observations, as reported by Liu
et al. (19).
Left ventricular mass was calculated at end diastole by
applying the Devereux correction to the ASE-cube LVM
formula (20,21). Relative wall thickness (RWT) was calcu-
lated as 2  posterior wall/end-diastolic diameter ratio, as
reported by Ganau et al. (22).
Only patients with normal LV systolic function were
included, whereas patients with both wall motion and
cardiac valve abnormalities were excluded from the study.
Genotyping. Genomic DNA was isolated from 3 ml whole
blood following a standard procedure (23), with minor
modifications.
Allelic discrimination of the 344C/T CYP11B2 poly-
morphism was performed using a 5 nuclease assay on
an ABI Prism 7700 apparatus (Perkin Elmer, Norwalk,
Connecticut) (24). Forward and reverse primers and
344C and 344T probes used in the TaqMan assay
(Applied Biosystems, Foster City, California) were: 5-CTA-
A A T C T G T G G T A T A A A A A T A A A G T C T A T -
TAAAAGA; 5-TTTCTCCAGGGCTGAGAGGA;
5VIC-AAGGCCCCCTCTCATCTCACGATA-
TAMRA; and 5FAM-CAAGGCTCCCTCTC-
ATCTCACGATAAG-TAMRA, respectively. Per 25 ml,
polymerase chain reaction fluid contained 50 ng DNA,
300 nmol primers, 70 nmol FAM probe, and 50 nmol VIC
probe. Amplification conditions were 50°C for 2 min and
95°C for 10 min, followed by 40 cycles at 95°C for 15 min
and 62°C for 1 min.
Statistical analysis. All data are given as the mean value 
SEM. Differences between groups were analyzed with one-
Abbreviations and Acronyms
BP  blood pressure
LV  left ventricle/ventricular
LVH  left ventricular hypertrophy
LVM  left ventricular mass
PRA  plasma renin activity
PWT  posterior wall thickness
RWT  relative wall thickness
ST  septal thickness
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or two-way analysis of variance or analysis of co-variance, as
specified in the Results section. Deviation from Hardy-
Weinberg equilibrium, gender ratios, and the presence of
LVH were analyzed with the chi-square test. Continuous
variables were analyzed with simple and multiple regression.
Analysis was performed with SPSS version 10 for the
MacOS statistical software on an iMAC personal computer.
RESULTS
The frequencies of the344C and344T alleles were 46%
and 54%, respectively. Genotype frequencies for the
344C/T polymorphism are reported in Table 1. The
frequencies of the observed genotypes were not different
from those expected from the allele frequencies and Hardy-
Weinberg equilibrium (p 0.83). There were no significant
differences among the genotypes in terms of gender distri-
bution, body size, BP levels, age, and duration of hyperten-
sion. Among anthropometric and biochemical variables,
serum urate significantly decreased with an increase of T
alleles (p 0.02). Plasma aldosterone and PRA were similar
among the three groups, whereas the aldosterone/PRA ratio
was positively associated (p  0.03) with the number of T
alleles (Table 1). Neither plasma aldosterone, nor PRA, nor
the aldosterone/PRA ratio was correlated with cardiac
dimensions.
Table 2 summarizes the univariate analysis of variance for
cardiac dimensions according to the three genotypes and
shows that the CYP11B2 genotype was significantly asso-
ciated with LVM, ST, PWT, and RWT. Patients with the
TT genotype had the greatest values for these parameters,
whereas patients with the CT genotype had values greater
than did those with the CC genotype.
Moreover, coefficients of linear regression of CYP11B2
and ST, PWT, RWT, LVM, and aldosterone/PRA on the
Table 1. Anthropometric and Biochemical Variables According to the Three Genotypes
Variables 344CC 344CT 344TT p Value*
Genotype frequency 48 (22.9%) 97 (46.2%) 65 (31.0%) NS
Gender (M/F) 38/10 82/15 53/12 NS
Age (yrs) 40.4  1.6 42.3  1.0 44.2  1.1 NS
Estimated duration of hypertension (months) 32.9  7.7 28.1  5.8 33.6  7.6 NS
BMI (kg/m2) 25.5  0.4 24.9  0.3 24.8  0.3 NS
SBP (mm Hg) 144.0  2.1 145.3  1.4 147.6  1.9 NS
DBP (mm Hg) 97.1  1.5 97.1  1.0 97.3  1.1 NS
HR (beats/min) 78.8  1.6 73.0  1.0 75.2  1.4 0.01
Daytime SBP (mm Hg) 141.2  2.0 145.3  1.1 144.8  1.4 NS
Daytime DBP (mm Hg) 93.2  1.6 96.1  1.0 95.8  0.9 NS
Daytime HR (beats/min) 793.4  1.5 80.3  1.2 76.8  1.1 NS
sNa (mmol/l) 140.7  0.4 141.1  0.3 141.3  0.4 NS
sK (mmol/l) 4.23  0.05 4.13  0.03 4.18  0.04 NS
GFR (ml/min per BSA) 142.6  7.0 118.4  6.9 125.6  6.8 NS
BUN (mmol/l) 11.7  0.5 11.8  0.4 12.7  0.4 NS
sCholesterol (mmol/l) 5.3  0.2 5.4  0.2 5.3  0.1 NS
sHDL (mmol/l) 1.3  0.1 1.3  0.1 1.3  0.1 NS
sTriglyc. (mmol/l) 1.5  0.1 1.4  0.1 1.3  0.1 NS
sUrate (mol/l) 408.6  77.3 297.4  11.9 279.5  11.9 0.02
uNa (mmol/d) 186  11.6 169.1  8.6 153.0  7.9 NS
uK (mmol/d) 64.3  4.0 62.1  3.7 60.8  3.9 NS
PRA (mg/ml · h) 1.559  0.17 1.219  0.13 1.025  0.16 0.09
sAldost. (pg/ml) 121.8  12.2 102.3  9.7 113.6  11.5 NS
Aldosterone/PRA ratio 92.1  8.6 129.0  17.0 174.0  24.8 0.03
*By one-way analysis of variance. Data are presented as the mean value  SEM or number (%) of patients.
BMI  body mass index; BSA  body surface area; BUN  blood urea nitrate; DBP  diastolic blood pressure; GFR  glomerular filtration rate; HR  heart rate; NS
 not significant; PRA  plasmatic renin activity; sAldost.  plasmatic aldosterone; SBP  systolic blood pressure; sCholesterol  total plasmatic cholesterol; sHDL 
plasmatic high-density lipoprotein cholesterol; sK  plasmatic potassium; sNa  plasmatic sodium; sTriglyc.  plasmatic triglycerides; sUrate  plasmatic uric acid; uK
 24-h urinary potassium output; uNa  24-h urinary sodium output.
Table 2. Echocardiographic Variables According to the Three Genotypes
Variables 344CC 344CT 344TT p Value*
LV ST (cm) 0.99  0.02 1.03  0.02 1.08  0.03 0.04
LV PWT (cm) 0.93  0.03 0.95  0.01 1.03  0.02 0.002
EDD (cm) 4.91  0.08 4.95  0.06 4.85  0.06 NS
ESD (cm) 2.94  0.07 2.98  0.06 2.86  0.06 NS
LVM (g) 168  6.9 179  5.2 193  6.9 0.03
RWT (%) 38.3  1.2 38.8  0.8 42.8  1.1 0.004
*By one-way analysis of variance. Data are presented as the mean value  SEM.
EDD  end-diastolic diameter; ESD  end-systolic diameter; LV  left ventricular; LVM  left ventricular mass; NS 
not significant; RWT  relative wall thickness; ST  septal thickness.
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number of T alleles were all statistically significant, suggest-
ing that the T allele had an “additive effect” on these
parameters (Table 3).
To reduce the potential for bias due to confounding with
environmental factors, two-step multiple regression analyses
were performed. Septal thickness, PWT, RWT, and LVM
were considered one by one as the dependent variable in two
different regression models. In the first model, the indepen-
dent variables were age, gender, height, weight, BP, heart
rate, duration of hypertension, 24-h urinary sodium output,
and aldosterone/PRA ratio. In the second model, the
CYP11B2 genotype (defined as the number of T alleles) was
added to the equation, retaining all the variables considered
in first step. The regression coefficient associated with the
CYP11B2 genotype was statistically significant for all the
dependent variables. Specifically, the genotype effect ex-
plained 4.6%, 12.8%, 8.5%, and 4.9% of the total variability
for ST, PWT, RWT, and LVM, respectively. However, the
statistical significance of the whole model was reached for
ST, PWT, and LVM, but not for RWT (Table 4).
DISCUSSION
Our study demonstrates a positive relationship between the
aldosterone synthase polymorphism CYP11B2 and LV
mass, wall thicknesses, and RWT. Simple regression of
CYP11B2 polymorphism with cardiac variables shows an
“additive effect” of the T allele (e.g., the greater the number
of T alleles, the greater the value) for ST, PWT, RWT, and
LVM, suggesting a “major gene” behavior for CYP11B2
polymorphism. Multiple regression analysis showed that
this effect is independent of anthropometric and clinical
factors, including adrenal aldosterone. In particular,
CYP11B2 alone explained 4.6%, 12.8%, 8.5%, and 4.9% of
total variability for ST, PWT, RWT, and LVM, respec-
tively.
This is presently the first study to show a direct correla-
tion between CYP11B2 polymorphism and LVM in hyper-
tension. A previous report by Kupari et al. (14) reached
apparently opposite results, as patients bearing the CC
genotype showed a greater LVM. However, their study
subjects were normotensive, whereas we studied hyperten-
sive patients. We believe this difference cannot be disre-
garded, as different pathologic mechanisms may be respon-
sible for the development of LVH in these two populations.
In line with this hypothesis, LVM depended on the end-
diastolic diameter in Kupari’s patients (CC patients showed
a greater end-diastolic diameter, although there were no
differences in ST and PWT among the three genotypes),
whereas in our patients, LVM depended on ST and PWT
(TT patients showed a greater ST and PWT, although
there were no differences in end-diastolic diameter among
the three genotypes).
As far as we know, association studies comparing
CYP11B2 polymorphism to LVM resulted in controversial
results, even considering different hypertensive populations
(15–17). In our opinion, when relaxed selection criteria are
used when choosing subjects for analysis, the resulting
background noise may mask a possible genotype–phenotype
relationship. Consequently, contrasting results are not sur-
prising (15–17) if patients considered for the individual
studies differed in terms of race (15), presence of underlying
disease, age, or washout period (16), to obtain a complete
regression of cardiac changes pharmacologically induced (4).
For these reasons, restrictive inclusion criteria, such as those
requiring similar race, age, body dimensions, duration and
severity of hypertension, and dietary habits, as well as no
Table 3. Simple Regressions Between Cardiac Variables Versus CYP11B2
Dependent Variable R2 (%) Beta  SE Beta p Value
LV ST 2.9 0.47  0.19 0.17 0.01
LV PWT 4.9 0.51  0.16 0.22 0.001
ESD 0.5 0.5  0.48 0.07 NS
EDD 0.3 0.4  0.49 0.05 NS
LVM 3.2 12.6  4.93 0.18 0.01
RWT 4.2 0.02  0.01 0.20 0.003
Abbreviations as in Table 2.
Table 4. Multiple Regression Analysis
Dependent Variable
Model 1:
R2 (%)
Model 2:
R2 (%)
R2 Change (%)
(Genotype Effect)
Significance of
R2 Change
(p Value)
Significance of
Whole Model
(p Value)
LV ST 22.4 27.0 4.6 0.05 0.03
LV PWT 12.8 25.6 12.8 0.002 0.04
LVM 38.1 43.0 4.9 0.02 0.000
RWT 15.6 24.1 8.5 0.01 0.06
Each row represents the multiple regression of one individual cardiac parameter, considered as the dependent variable. For each dependent variable, the multiple regression is
performed in two models: 1) in model 1, the confounding variables considered are age, gender, height, weight, blood pressure, heart rate, duration of hypertension, 24-h urinary
sodium output and the aldosterone/plasma renin activity ratio; 2) in model 2, the confounding variables considered are all of the variables in model 1 plus the aldosterone synthase
genotype 11CYPB2.
Abbreviations as in Table 2.
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previous pharmacologic treatment, may facilitate the eluci-
dation of genotype–phenotype relations, as in our study. To
our knowledge, the only previous study (17) published with
similarly restrictive recruitment criteria showed a trend
similar to ours. Delles et al. (17) analyzed a small group of
very young hypertensives matched to normotensives. They
found greater values of cardiac diameters and an inadequate
level of aldosterone secretion after sodium loading in hy-
pertensive patients bearing the CC genotype, as compared
with the other genotypes. No genotype differences were seen
among normotensives. However, when the Delles’ data are
examined in depth, a trend similar to that found in our study
is observed for LV septal and posterior wall thickening. In
both of these studies, these parameters increased with the
number of T alleles among hypertensive patients, although
statistical significance was not reached. A lack of statistical
significance in the Delles’ study may be explained by both
the reduced size of their sample and a different stage of
hypertension (inasmuch as their patients were younger than
the patients included in our study). Indeed, it is well known
that each phase of the development of hypertension is
characterized by different hemodynamic changes inducing
different echocardiographic patterns (25).
To further strengthen the interpretation of the results
from association studies, it is important to establish a
plausible biologic explanation for a statistical relationship
between the marker genotypes and the intermediate phe-
notypes related to the disease, trying to clarify the patho-
physiologic meaning of the observed associations.
In the present study, a positive association between
CYP11B2 and aldosterone/PRA was found, suggesting a
possible regulatory role of adrenal aldosterone secretion for
this polymorphism, as previously reported by some investi-
gators (26,27), though with some contrasting results (28).
The relationship between plasma aldosterone and LVH and
fibrosis is well known (6–8). However, in our patients, no
associations between cardiac dimensions and PRA, plasma
aldosterone, or the aldosterone/PRA ratio were found,
suggesting that LVH and wall thickening are not dependent
on adrenal aldosterone production in these patients. Recent
observations underlie the role for aldosterone’s intracardiac
synthesis in the pathogenesis of hypertrophy and fibrosis.
This synthesis is regulated by an intracardiac aldosterone
synthase, which seems modulated by CYP11B2 polymor-
phism (10–12). Thus, although indirectly, our data seem to
support the hypothesis of a primary role of intracardiac
aldosterone secretion that CYP11B2 modulated in the
development of LVM, whereas adrenal aldosterone may not
be that relevant. It is possible to hypothesize that CYP11B2
regulates aldosterone synthesis in different organs. In par-
ticular, at the adrenal level, it could regulate body volumes
by controlling aldosterone secretion, whereas at the cardiac
level, it could directly contribute to the increase of LVM
and thicknesses by regulating aldosterone’s paracrine pro-
duction. Although cardiac aldosterone production has been
found to be increased in hypertensives compared with
normotensives (12), only measured plasmatic aldosterone
(i.e., adrenal production) was measured in our patients.
Thus, additional studies on cardiac aldosterone are needed
to confirm the hypothesis suggested by this association
study.
Conclusions. The present study demonstrates an associa-
tion between CYP11B2 polymorphism and LVH. The
association seems to be independent of adrenal aldosterone
production and suggests a role for cardiac aldosterone
production.
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